Navigation Links
DrugRisk Update: Panel To Decide Fate of Januvia Lawsuits Next Week
Date:6/22/2013

New York, NY (PRWEB) June 22, 2013

The diabetes drug safety advocates at DrugRisk.com are announcing new information on the site for those patients taking the medications Januvia or Janumet. A federal panel will meet next week to decide which court venue will handle growing lawsuits alleging the drugs caused cancer*.

The goal of DrugRisk is to improve the safety of patients taking popular prescription drugs like Januvia and Janumet by providing the latest warnings, recalls, studies and legal news. Visitors can see if others are experiencing similar side effects and decide if they need legal advice.

Januvia and Janumet are pill-form diabetes medications prescribed to help those with type-2 diabetes control blood sugar. The drugs were two of the best-selling for Merck in recent years, with sales of over $4 billion last year**.

The resource center contains studies suggesting Januvia and Janumet may be linked to cancer. A 2011 study from UCLA indicated the drug could increase the risk of pancreatic cancer by 172% and thyroid cancer by 48%***. The FDA is also investigating the risk of Janumet and Januvia cancer after receiving reports that some patients who died showed signs of early pancreatic cancer cells****.

DrugRisk also added a report by Dr. Peter Butler, head of endocrinology at UCLA, warning that the Januvia pancreatic cancer risk was not detected in trials prior to FDA approval because the manufacturer used very young animals not as prone to pancreatic cancer*****.

Now, with 53 patients having already filed a Januvia lawsuit alleging cancer, the Judicial Panel on Multidistrict Litigation will meet on July 25th to determine where to consolidate the growing number of cases*. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, United States Judicial Panel on Multidistrict Litigation).

Anyone affected by cancer after taking Januvia or Janumet is encouraged to speak with a lawyer about their legal options. However, due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who have already handled Januvia lawsuits.

For more information on the research, side effects and litigation news related to Januvia and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*JPML, 6/12/13; jpml.uscourts.gov/sites/jpml/files/Hearing_Order-7-25-13.pdf
**Bloomberg, 2/25/13; bloomberg.com/news/2013-02-25/merck-bristol-diabetes-drugs-linked-to-pancreatitis-risk.html
***Gastroenterology, July 2011; ctsi.ucla.edu/education/files/publicview/training/docs/FDA-analysis.pdf
****FDA, 3/14/13; http://www.fda.gov/Drugs/DrugSafety/ucm343187.htm
*****New York Times, 5/31/13; nytimes.com/2013/05/31/business/a-doctor-raises-questions-about-a-diabetes-drug.html?hp&_r=1&

Read the full story at http://www.prweb.com/releases/januvia-lawsuit/pancreatic-thyroid-cancer/prweb10859222.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Center Announces Court Postponement of NuvaRing Lawsuits
2. DrugRisk Announces Alternative to Mirena IUD May Be Available Soon
3. DrugRisk Announces Updated Information on Mirena Lawsuits
4. DrugRisk Adds Latest Health Warnings and Lawsuit Updates for Yaz
5. DrugRisk Announces New Pradaxa Health Warning From Australia
6. DrugRisk Update: NuvaRing Lawsuit Trials to Begin This Year
7. DrugRisk Update: Court Allows Charges of Prior Fraud Into Pradaxa Lawsuit
8. DrugRisk Pradaxa Lawsuit Update: Court Denys Boehringer’s Protective Order Request
9. DrugRisk Pradaxa Update: Litigation Grows As New Study Adds to Risks
10. DrugRisk Update: Bayer Discloses $500 Million Remaining for Yaz Lawsuits
11. DrugRisk Update: Evidence Submitted in Actos Lawsuit Suggests Drug Maker Knew of Cancer Risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... The Gallery ... Kevin Sadati, is pleased to announce a new treatment option called Vivace Microneedling. ... their face, neck, and body through a virtually pain-free, non-surgical treatment. Vivace Microneedling ...
(Date:5/23/2017)... ... May 23, 2017 , ... New patients from Charleston, SC, are ... dentist practicing in Mt. Pleasant, SC, with or without a referral. A full mouth ... with missing teeth in Charleston, SC. Those who suffer from gum disease, ...
(Date:5/23/2017)... WI (PRWEB) , ... May 23, 2017 , ... Patients ... to call Dr. Angela Cotey’s practice to schedule an appointment, with or without a ... and frequently offers pulpotomy treatments to pediatric patients as a healthy alternative to a ...
(Date:5/22/2017)... PA (PRWEB) , ... May 22, 2017 , ... An ... to write with a pen. "My wife’s hand was damaged in a firework accident, ... something that helps people with manual problems." , He then designed and created a ...
(Date:5/22/2017)... ... May 22, 2017 , ... ... larger group investing in InsightRX, an early stage company in San Francisco that ... pharmacological characteristics. Greatpoint Ventures Innovation Fund acted as the lead investor ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)...  Two Bayer U.S. Pharmaceutical leaders received top awards ... 28 th Woman of the Year ... longstanding mission of furthering the advancement and impact of ... Cindy Powell-Steffen , senior director of brand activation and ... Libby Howe , a regional business manager for New ...
(Date:5/15/2017)... Inc., a privately-held CNS pharmaceutical company based in ... disease (PD), has enrolled the first patient in the RASMET ... study involving patients with PD and taking place at 12 ... period. The first stage is open label and involves single ... Denver , Boca Raton ...
(Date:5/10/2017)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... quarter ended April 1, 2017 .   GAAP diluted ... to the prior year period as the sale of ... while non-GAAP diluted EPS of $0.50 increased 6.4%.  Revenue ... currency terms.  Excluding the effects of blood screening and ...
Breaking Medicine Technology: